Pliant Therapeutics, Inc. (PLRX): Total Liabilities
$44.02M
As of 2025-12-31
$42.95M
As of 2026-06-30
+5.7%
3-year compound annual growth
+28.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.02M | -52.6% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $92.87M | +140.7% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $38.58M | +3.5% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $37.27M | +68.2% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $22.16M | +77.7% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $12.46M | +37.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $9.08M | n/a | 2021-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $44.02M | -52.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare PLRX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗